Read by QxMD icon Read

circulating tumors cells and colorectal liver metastases

Klaas M Govaert, Jennifer M J Jongen, Onno Kranenburg, Inne H M Borel Rinkes
Metastatic colorectal cancer (mCRC) is a devastating disease causing 700.000 deaths annually worldwide. Metastases most frequently develop in the liver. Partial hepatectomy has dramatically improved clinical outcome and is the only curative treatment option for eligible patients with mCRC. Pre-clinical studies have shown that surgical procedures can have tumor-promoting local 'side-effects' such as hypoxia and inflammation, thereby altering the behaviour of residual tumor cells. In addition, systemically released factors following (colon or liver) surgery can act as a wakeup-call for dormant tumor cells in distant organs and/or help establish a pre-metastatic niche...
December 2017: Surgical Oncology
Chao Fang, Chuanwen Fan, Cun Wang, Qiaorong Huang, Wentong Meng, Yongyang Yu, Lie Yang, Jiankun Hu, Yuan Li, Xianming Mo, Zongguang Zhou
In the previous study, we had showed the expression of CD133+ CD54+ CD44+ cellular subpopulation of circulating tumor cells (CTCs) was significantly associated with liver metastasis of colorectal cancer (CRC). This study aimed to explore whether this subpopulation of CTCs have a prognostic value in CRC patients. Flow cytometry was used to detect the expression of cellular subpopulations of CTCs with CD133, CD54, and CD44 in 152 CRC patients, between December 2013 and October 2014. The impact of clinicopathological factors and the expression of cellular subpopulations of CTCs on overall survival were then analyzed...
December 2017: Cancer Medicine
(no author information available yet)
Assessing circulating tumor DNA (ctDNA) is a promising method to evaluate somatic mutations from solid tumors in a minimally-invasive way. In a group of twelve metastatic colorectal cancer (mCRC) patients undergoing liver metastasectomy, from each patient DNA from cell-free DNA (cfDNA), the primary tumor, metastatic liver tissue, normal tumor-adjacent colon or liver tissue, and whole blood were obtained. Investigated was the feasibility of a targeted NGS approach to identify somatic mutations in ctDNA. This targeted NGS approach was also compared with NGS preceded by mutant allele enrichment using synchronous coefficient of drag alteration technology embodied in the OnTarget assay, and for selected mutations with digital PCR (dPCR)...
December 2016: Molecular Oncology
Rosa Divella, Antonella Daniele, Raffaele DE Luca, Michele Simone, Emanuele Naglieri, Eufemia Savino, Ines Abbate, Cosmo Damiano Gadaleta, Girolamo Ranieri
Colorectal cancer is the most common cancer of the gastrointestinal system and has a marked preference to metastasize to distant organs. In this study, we investigated whether levels of circulating serum pro-angiogenic cytokine such as chemokine (C-X-C motif) ligand 1 (melanoma growth-stimulating activity, alpha; CXCL1) and vascular endothelial growth factor (VEGF) have a role in favoring the colonization of metastatic cells at preferential sites and determined their prognostic significance in a cohort of 103 patients with metastatic colorectal cancer...
September 2017: Anticancer Research
Nuh N Rahbari, Sebastian Schölch, Ulrich Bork, Christoph Kahlert, Martin Schneider, Mohammad Rahbari, Markus W Büchler, Jürgen Weitz, Christoph Reissfelder
BACKGROUND: There is urgent need for improved staging in patients with metastatic colorectal cancer (mCRC). In this study, we evaluated the prognostic value of circulating endothelial cells (CEC) in comparison with circulating tumor cells (CTC) in patients with mCRC amenable for potentially curative surgery. METHODS: A total of 140 patients were enrolled prospectively. CTC and CEC were measured with the CellSearch System (Veridex, NJ, USA). Cut-off values were determined using ROC analyses...
June 6, 2017: Oncotarget
Torhild Veen, Kjetil Søreide
In resectable colorectal liver metastasis (CRLM) the role and use of molecular biomarkers is still controversial. Several biomarkers have been linked to clinical outcomes in CRLM, but none have so far become routine for clinical decision making. For several reasons, the clinical risk score appears to no longer hold the same predictive value. Some of the reasons include the ever expanding indications for liver resection, which now increasingly tend to involve extrahepatic disease, such as lung metastases (both resectable and non-resectable) and the shift in indication from "what is taken out" (e...
March 15, 2017: World Journal of Gastrointestinal Oncology
Lars Thomas Seeberg, Cathrine Brunborg, Anne Waage, Harald Hugenschmidt, Anne Renolen, Ingunn Stav, Bjørn A Bjørnbeth, Elin Borgen, Bjørn Naume, Kristoffer W Brudvik, Gro Wiedswang
OBJECTIVE: The aim of this study was to analyse the survival impact of primary tumor nodal status (N0/N+) in patients with resectable colorectal liver metastases (CLM), and to determine the value of circulating and disseminated tumor cells (CTCs/DTCs) in this setting. METHODS: In this prospective study of patients undergoing resection of CLM from 2008 to 2011, peripheral blood was analyzed for CTCs using the CellSearch System®, and bone marrow was sampled for DTC analyses just prior to hepatic resection...
August 2017: Annals of Surgical Oncology
Ashley M Mohr, John J Gould, Jacy L Kubik, Geoffrey A Talmon, Carol A Casey, Peter Thomas, Dean J Tuma, Benita L McVicker
Metastatic liver disease is a major cause of mortality in colorectal cancer (CRC) patients. Alcohol consumption is a noted risk factor for secondary cancers yet the role of alcoholic liver disease (ALD) in colorectal liver metastases (CRLM) is not defined. This work evaluated tumor cell colonization in the alcoholic host liver using a novel preclinical model of human CRC liver metastases. Immunocompromised Rag1-deficient mice were fed either ethanol (E) or isocaloric control (C) diets for 4 weeks prior to intrasplenic injection of LS174T human CRC cells...
February 2017: Clinical & Experimental Metastasis
Nick Beije, Jean C Helmijr, Marjolein J A Weerts, Corine M Beaufort, Matthew Wiggin, Andre Marziali, Cornelis Verhoef, Stefan Sleijfer, Maurice P H M Jansen, John W M Martens
Assessing circulating tumor DNA (ctDNA) is a promising method to evaluate somatic mutations from solid tumors in a minimally-invasive way. In a group of twelve metastatic colorectal cancer (mCRC) patients undergoing liver metastasectomy, from each patient DNA from cell-free DNA (cfDNA), the primary tumor, metastatic liver tissue, normal tumor-adjacent colon or liver tissue, and whole blood were obtained. Investigated was the feasibility of a targeted NGS approach to identify somatic mutations in ctDNA. This targeted NGS approach was also compared with NGS preceded by mutant allele enrichment using synchronous coefficient of drag alteration technology embodied in the OnTarget assay, and for selected mutations with digital PCR (dPCR)...
October 10, 2016: Molecular Oncology
Gabriela Vojtechova, Lucie Benesova, Barbora Belsanova, Petra Minarikova, Miroslav Levy, Ludmila Lipska, Stepan Suchanek, Miroslav Zavoral, Marek Minarik
BACKGROUND: The presence of circulating tumor cells (CTC) has been reported in patients with advanced colorectal cancer. Monitoring CTC (also known as a liquid-biopsy) has recently become the center of interest for low-invasive monitoring of cancer progression and predictive biomarkers testing. Along with high-cost technology and a complex methodology, a straightforward method based on magnetic beads enrichment followed by RT-PCR is set to allow for routine CTC analysis in colorectal cancer patients...
November 2016: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
E Janowski, O Timofeeva, S Chasovskikh, M Goldberg, A Kim, F Banovac, D Pang, A Dritschilo, K Unger
Patients with unresectable, chemo-refractory colorectal cancer liver metastases (CRCLM) have limited local treatment options. We report our institutional experience on the efficacy of resin-based yttrium-90 (90Y) radioembolization for the treatment of CRCLM and our findings on associated circulating cell-free DNA (ccfDNA) studies. A total of 58 patients treated with 90Y for CRCLM at the Medstar Georgetown University Hospital had a median survival of 6 months [95% confidence interval (CI), 4.55‑7.45 months] after treatment, with a 12-month survival rate of 33%...
January 2017: Oncology Reports
Yasumasa Takii, Satoshi Maruyama, Hitoshi Nogami
Surgical resection is the only curative treatment modality for colorectal cancer limited locally. Evidence for the kind of resection procedure that is effective for improving prognosis is insufficient. Prognosis improvement is expected with the no-touch isolation technique (NTIT), making it the most important resection procedure. We are conducting a multicenter randomized controlled trial (RCT) to confirm the efficacy of NTIT in patients with colorectal cancer. The present review serves as a preface to our trial, as it focuses on basic and clinical studies that support the efficacy of NTIT...
August 27, 2016: World Journal of Gastrointestinal Surgery
Lejla Alidzanovic, Patrick Starlinger, Dominic Schauer, Thomas Maier, Alexandra Feldman, Elisabeth Buchberger, Judith Stift, Ulrike Koeck, Lorand Pop, Birgit Gruenberger, Thomas Gruenberger, Christine Brostjan
Vascular endothelial growth factor (VEGF) has become a major target in cancer treatment as it promotes tumor angiogenesis. Therapy with anti-VEGF antibody bevacizumab reportedly induces high levels of circulating VEGF which may potentially contribute to resistance. Based on animal or computational models, mechanisms of VEGF induction by bevacizumab have been proposed but not verified in the clinical setting. Hence, we evaluated sixty patients with colorectal cancer metastases for changes in plasma VEGF during neoadjuvant/conversion and adjuvant chemotherapy with or without bevacizumab...
August 30, 2016: Oncotarget
Wendy Onstenk, Anieta M Sieuwerts, Bianca Mostert, Zarina Lalmahomed, Joan B Bolt-de Vries, Anne van Galen, Marcel Smid, Jaco Kraan, Mai Van, Vanja de Weerd, Raquel Ramírez-Moreno, Katharina Biermann, Cornelis Verhoef, Dirk J Grünhagen, Jan N M IJzermans, Jan W Gratama, John W M Martens, John A Foekens, Stefan Sleijfer
BACKGROUND: CTCs are a promising alternative for metastatic tissue biopsies for use in precision medicine approaches. We investigated to what extent the molecular characteristics of circulating tumor cells (CTCs) resemble the liver metastasis and/or the primary tumor from patients with metastatic colorectal cancer (mCRC). RESULTS: The CTC profiles were concordant with the liver metastasis in 17/23 patients (74%) and with the primary tumor in 13 patients (57%). The CTCs better resembled the liver metastasis in 13 patients (57%), and the primary tumor in five patients (22%)...
September 13, 2016: Oncotarget
Ludovic Moro-Sibilot, Pascal Blanc, Morgan Taillardet, Emilie Bardel, Coline Couillault, Gilles Boschetti, Alexandra Traverse-Glehen, Thierry Defrance, Dominique Kaiserlian, Bertrand Dubois
BACKGROUND & AIMS: The liver receives blood from the gastrointestinal tract through the portal vein, and thereby is exposed continuously to dietary antigens and commensal bacteria. Alcoholic liver disease (ALD) is associated with intestinal dysbiosis, increased intestinal permeability, release of microbes into the portal circulation, and increased serum levels and liver deposits of IgA. We characterized B-cell production of IgA in livers of mice at homeostasis, after oral immunization, in a mouse model of ALD and in human liver samples...
August 2016: Gastroenterology
Bin Ma, Longyi Wang, Peng Gao, Yongxi Song, Zhenning Wang
No abstract text is available yet for this article.
August 2016: International Journal of Colorectal Disease
Ashton A Connor, Kate McNamara, Eisar Al-Sukhni, Jacob Diskin, David Chan, Colleen Ash, Lori E Lowes, Alison L Allan, George Zogopoulos, Carol-Anne Moulton, Steven Gallinger
BACKGROUND: Colorectal cancer liver metastases (CRLMs) are potentially curable with resection, but most patients recur and succumb to their disease. Clinical covariates do not account for all outcomes. Circulating tumor cells (CTCs) are prognostic in the primary and metastatic settings of breast, prostate and colorectal cancer (CRC), and evolving evidence supports their role in CRLMs. Our objective was to determine whether CTCs in peripheral (PV) and hepatic venous (HV) compartments are associated with disease-free survival (DFS) and overall survival (OS) post-CRLM resection...
July 2016: Annals of Surgical Oncology
Sebastian Hinz, Jürgen Tepel, Christian Röder, Holger Kalthoff, Thomas Becker
BACKGROUND/AIM: The degree of systemic response after hepatic radiofrequency ablation (RFA) has not been well-compared to liver resection so far. This pilot study was designed to examine whether RFA, compared to liver resection, significantly varies concerning dissemination of circulating tumor cells and induction of different pro-inflammatory markers and liver-specific growth factors. PATIENTS AND METHODS: Patients with colorectal liver metastases were treated with RFA, a combination of RFA and resection or liver resection only...
May 2015: Anticancer Research
Brice Malgras, Laura Brullé, Réa Lo Dico, Fatima El Marjou, Sylvie Robine, Amu Therwath, Marc Pocard
BACKGROUND: Colonic self-expanding metallic stents (SEMS) are used in obstructive colorectal cancer patients as a bridge to surgery. However, its oncologic safety remains uncertain. Therefore, we attempted to clarify this further with an experimental study and constructed a mouse model of colonic cancer. METHODS: CT26 cells were injected in the rectal wall, and to mimic SEMS, a cardiac stent was inserted under endoscopy in occlusive (75 % lumen occlusion) tumors...
December 2015: Annals of Surgical Oncology
Jussuf T Kaifi, Miriam Kunkel, Avisnata Das, Ramdane A Harouaka, David T Dicker, Guangfu Li, Junjia Zhu, Gary A Clawson, Zhaohai Yang, Michael F Reed, Niraj J Gusani, Eric T Kimchi, Kevin F Staveley-O'Carroll, Si-Yang Zheng, Wafik S El-Deiry
BACKGROUND: Colorectal cancer (CRC) metastasectomy improves survival, however most patient develop recurrences. Circulating tumor cells (CTCs) are an independent prognostic marker in stage IV CRC. We hypothesized that CTCs can be enriched during metastasectomy applying different isolation techniques. METHODS: 25 CRC patients undergoing liver (16 (64%)) or lung (9 (36%)) metastasectomy were prospectively enrolled ( identifier: NCT01722903). Central venous (liver) or radial artery (lung) tumor outflow blood (7...
2015: Cancer Biology & Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"